Lv1
40 积分 2025-05-17 加入
Reframing the High-density Lipoprotein (HDL) Hypothesis in Light of Clinical Trials of Cholesterol Ester Transfer Protein (CETP) Inhibitors
3个月前
已完结
Lipoprotein(a)-lowering therapies: a promising future
4个月前
已完结
Assessment of LDL receptor-dependent lipid lowering therapies in patients with homozygous familial hypercholesterolemia according to functional genotype
5个月前
已关闭
Age and sex influence transcriptomic responses to statin therapy that control liver aging during systemic metabolic dysfunction
5个月前
已完结
The Inherited Basis of Coronary Artery Disease
6个月前
已完结
The Inherited Basis of Coronary Artery Disease
6个月前
已完结
Cardiovascular-Kidney-Metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD
7个月前
已完结
Targeting Modulated Vascular Smooth Muscle Cells in Atherosclerosis via FAP-Directed Immunotherapy
7个月前
已完结
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial
8个月前
已完结
On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors
9个月前
已完结
皖公网安备34019202002308
